Hepatitis E News and Research

RSS

Hepatitis E is a viral hepatitis (liver inflammation) caused by infection with a virus called hepatitis E virus (HEV).

Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting

Vertex Pharmaceuticals Incorporated today announced that abstracts from its hepatitis C program, including two late-breaking posters from studies of INCIVEK (telaprevir) tablets and VX-222, were accepted for presentation at The Liver Meeting, the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, November 4-8, 2011.

1 Oct 2011

Patients with chronic hepatitis C less likely to take medications over time

Patients being treated for chronic hepatitis C become less likely to take their medications over time, according to a new study from the Perelman School of Medicine at the University of Pennsylvania.

30 Sep 2011

Researchers determine structure of RIG-I protein linked with viral infections

Researchers at Rutgers and UMDNJ-Robert Wood Johnson Medical School have determined the structure of a protein that is the first line of defense in fighting viral infections including influenza, hepatitis C, West Nile, rabies, and measles.

30 Sep 2011

Sexually transmitted infection epidemic worries health experts

Researchers at the University of New South Wales (NSW) revealed that new cases of gonorrhea and Chlamydia are on the rise in Australia, particularly among young members of indigenous communities.

29 Sep 2011

AASLD publishes updated practice guidelines on hepatitis C

On Monday, September 26, 2011, the American Association for the Study of Liver Diseases published online at its journal Hepatology's website an update to its practice guidelines for hepatitis C – "An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases."

29 Sep 2011

Long-term morbidity and mortality of NAFLD patients with advanced fibrosis, cirrhosis

Patients with non-alcoholic fatty liver disease (NAFLD) with advanced fibrosis or cirrhosis have a lower incidence of liver-related complications and hepatocellular carcinoma (HCC) than patients infected with hepatitis C virus (HCV), according to the prospective study published in the October issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

28 Sep 2011

Liver transplantation candidates without HCC derive greater survival benefit from LDLT

New research shows liver transplantation candidates without hepatocellular carcinoma (HCC) derive a greater survival benefit from a living donor liver transplant (LDLT) than waiting for a deceased donor liver transplant.

28 Sep 2011

State roundup: Consumer advocates oppose Ga. request to ease rules on insurers' profits

The state's request to ease new federal restrictions on health insurer spending would cost Georgia insurance policyholders an estimated $34 million in rebates, consumer advocacy groups say.

22 Sep 2011

New FDA-approved antiviral drugs offer treatment hope for hepatitis C

The Methodist Hospital in Houston is excited to share significant news for patients who need treatment for hepatitis C genotype 1, a viral infection that causes liver inflammation that can lead to diminished liver function or symptoms for liver failure.

21 Sep 2011

Antivirals from shark cartilage compound squalamine

A unique compound originally isolated from sharks could prove to be a promising treatment for hepatitis B and C and other viral diseases, researchers say. Known as squalamine, the drug has not yet been tested as an antiviral agent in humans, but it has been given to hundreds of people enrolled in clinical trials designed to test its usefulness for other conditions. Researchers say they hope to begin human trials to test the compound’s antiviral activity within the next year.

21 Sep 2011

Financial and political commitments to improve health of women and children

In only one year, more than 100 countries, foundations, multilateral organizations, the UN, the private sector, and academic and professional associations have made unprecedented financial and political commitments to greatly improve the health of women and children.

21 Sep 2011

Scientists discover how liver destroys immune T-cells

Scientists at the Centenary Institute in Sydney have seen for the first time (in mice) how the liver goes independent, engulfing and destroying the body's defence troops-T-cells.

20 Sep 2011

Chronic diseases could cost $47 trillion over the next 20 years: Report

A latest report by the World Economic Forum (WEF) suggests that the global economic impact of the five leading chronic diseases -- cancer, diabetes, mental illness, heart disease, and respiratory disease - could reach $47 trillion over the next 20 years.

19 Sep 2011

Georgia reminds adults to get vaccinated

Vaccines aren't just for kids, adults need protection too! September 18 kick starts National Adult Immunization Awareness Week and the Georgia Department of Public Health reminds Georgians that you never outgrow the need for vaccines.

16 Sep 2011

Teva to invest in CDI for development of novel antiviral drugs

Teva Pharmaceutical Industries Ltd. announced today that it has signed a collaboration option to license and share purchase agreements to invest in Cocrystal Discovery Inc. (CDI), a biopharmaceutical company focused on the discovery and development of novel antiviral therapeutics for the treatment of serious and chronic viral diseases.

16 Sep 2011

Shorter treatment with telaprevir-based combination regimen may benefit hepatitis C patients

Treatment with a telaprevir-based combination regimen for hepatitis C - heretofore a chronic, destructive and difficult to manage disease - effectively can be shortened to six months in about two-thirds of patients, finds a new study published Thursday in the New England Journal of Medicine.

16 Sep 2011

Experimental malaria vaccine shows positive results among children in small Burkina Faso study

"An experimental malaria vaccine tested on children in Burkina Faso has shown 'a high level of efficacy' in protecting against the disease, a study published in" Thursday's New England Journal of Medicine said, according to Agence France-Presse.

16 Sep 2011

VBI Vaccines completes acquisition of Epixis

VBI Vaccines (VBI), a biotechnology company dedicated to the innovative formulation, development and delivery of safe and effective vaccines, announced today that it has completed the acquisition of Epixis S.A., a French biotechnology company developing its "eVLP" platform technology for a new generation of Virus-Like Particle (VLP) vaccines.

15 Sep 2011

Patients with hepatitis C may benefit from 24 week telaprevir-based regimen

University of Cincinnati research published in the Sept. 14, 2011, advance online edition of the New England Journal of Medicine shows that patients with hepatitis C who took a combination medication-a telaprevir-based regimen that is commonly used to treat the illness-for 24 weeks were cured.

15 Sep 2011

NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C

Vertex Pharmaceuticals Incorporated today announced that the New England Journal of Medicine (NEJM) published data from a Phase 3 study of INCIVEK (telaprevir) tablets in people with genotype 1 chronic hepatitis C who were new to treatment.

15 Sep 2011